CRG 022
Alternative Names: CD22-CAR-T-cell-therapy; CRG-022Latest Information Update: 14 Jul 2024
At a glance
- Originator CARGO Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II B-cell lymphoma
- Phase I Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 14 Jul 2024 3862623- No update as abstract contains trial design
- 17 Oct 2023 CARGO Therapeutics plans clinical trials in Diffuse large B-cell lymphoma and other Haematological malignancies (Early-stage disease)
- 01 Aug 2023 Phase-II clinical trials in B-cell lymphoma (Second-line therapy or greater) in USA (IV) (NCT05972720)